Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Stat Biopharm Res. 2014 May 27;6(2):185–197. doi: 10.1080/19466315.2014.906365

Table 4.

MTD Recommendation and in-trial allocation for scenario B

	Group 1						Group 2
	d₁	d₂	d₃	d₄	d₅	d₆	d₁	d₂	d₃	d₄	d₅	d₆
R_i(d_k)	.08	.20	.35	.50	.70	.80	.01	.05	.18	.40	.55	.70
	Ratio of N₁/N₂ = 20/12
Prop (MTD)
Scheme I	2	50	47	1	0	0	2	50	47	1	0	0
Scheme II	17	51	30	2	0	0	2	15	57	24	3	0
Scheme III	16	55	29	1	0	0	1	28	63	9	0	0
Scheme IV	20	59	20	1	0	0	1	23	65	12	0	0
Prop (pts)
Scheme I	11	36	43	8	1	0	11	37	42	8	1	0
Scheme II	25	33	32	9	1	0	13	14	43	24	5	0
Scheme III	24	37	33	6	0	0	7	25	44	19	5	0
Scheme IV	26	43	27	4	0	0	5	21	51	20	3	0
	Ratio of N₁/N₂ = 16/16
Prop (MTD)
Scheme I	2	39	56	3	0	0	2	39	56	3	0	0
Scheme II	18	49	30	3	0	0	0	14	63	22	2	0
Scheme III	17	49	33	2	0	0	1	25	68	7	0	0
Scheme IV	23	52	24	1	0	0	0	23	70	7	0	0
Prop (pts)
Scheme I	9	30	48	11	1	0	10	31	47	11	1	0
Scheme II	27	30	31	11	2	0	10	13	47	25	5	0
Scheme III	23	35	36	7	0	0	6	24	48	18	4	0
Scheme IV	27	40	28	5	0	0	0	21	53	18	3	0